SCHEMBL4862824

SCHEMBL4862824

COc1ccc(CC(O)CN2CCN(CC(=O)Nc3cccc4ccccc34)CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.59
KMT2A Q03164 7/20 0.54
MEN1 O00255 5/20 0.54
MAPT P10636 5/20 0.54
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 2/20 0.53
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2D6 P10635 1/20 0.50
LMNA P02545 2/20 0.49
POLB P06746 2/20 0.49
MAPK1 P28482 1/20 0.49
PPARG P37231 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NR2E3 Q9Y5X4 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30585262 0.86 CYP2C19 (0.66) CYP2C19KMT2AMEN1MAPTALDH1A1
SCHEMBL29078410 0.86 CYP2C19 (0.66) CYP2C19KMT2AMEN1MAPTALDH1A1
SCHEMBL6284296 0.82 CYP2D6 (0.64) KMT2AMEN1ALDH1A1KDM4ECYP3A4
SCHEMBL4866581 0.82 CYP3A4 (0.60) CYP2C19KMT2AMEN1MAPTALDH1A1
SCHEMBL4491381 0.81 LMNA (0.70) KMT2AMEN1CYP2D6LMNAPPARG
SCHEMBL4867116 0.81 CYP3A4 (0.71) CYP2C19KMT2AMEN1MAPTALDH1A1
SCHEMBL4483819 0.78 ALDH1A1 (0.58) KMT2AALDH1A1KDM4EPOLB
SCHEMBL4490433 0.77 KMT2A (0.63) KMT2AMEN1MAPTALDH1A1CYP2D6
SCHEMBL5224753 0.77 ALDH1A1 (0.56) CYP2C19KMT2AMEN1MAPTALDH1A1
SCHEMBL4496607 0.76 LMNA (0.60) KMT2AMEN1ALDH1A1CYP2D6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A CYP2C19 317/4885KMT2A 3201/4885MEN1 3200/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A CYP2C19 298/4885KMT2A 3029/4885MEN1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.